Huahai Pharmaceutical announced that recently, the company received the “Drug Registration Certificate” for benidipine hydrochloride tablets approved and issued by the State Drug Administration. The drug is used to treat essential hypertension and angina pectoris. It was approved for marketing in China in March 2004, and the market sales amount in 2025 is about 1,172 billion yuan. The company invested about 7.07 million yuan in R&D in this project. This approval is regarded as passing the consistency evaluation, which will enrich the product line and enhance competitiveness, but production and sales are easily affected by policy and market factors.

Huahai Pharmaceutical announced that recently, the company received the “Drug Registration Certificate” for benidipine hydrochloride tablets approved and issued by the State Drug Administration. The drug is used to treat essential hypertension and angina pectoris. It was approved for marketing in China in March 2004, and the market sales amount in 2025 is about 1,172 billion yuan. The company invested about 7.07 million yuan in R&D in this project. This approval is regarded as passing the consistency evaluation, which will enrich the product line and enhance competitiveness, but production and sales are easily affected by policy and market factors.